Weight-Loss drug tirzepatide may cut AFib recurrence after ablation in obese patients

This study tests whether tirzepatide, a weight-loss medication, can reduce the amount of time people with persistent atrial fibrillation (an irregular heartbeat) spend in abnormal heart rhythm after a catheter ablation procedure. About 200 overweight or obese adults will receive either tirzepatide injections plus standard care, or standard care alone, starting 4 weeks before ablation and continuing for 3 months after. Researchers will monitor heart rhythm, weight, and metabolic health over a year to see if the drug improves outcomes.